Partnering for Potential Access: Dapivirine Ring

IPM’s most advanced microbicide, the monthly dapivirine ring, is now under regulatory review for potential licensure. Market introduction efforts for other health and medical products have shown the need to meaningfully engage key stakeholders in order to minimize access delays.

IPM is applying these lessons and partnering with Johnson & Johnson, which granted IPM exclusive worldwide rights to dapivirine, to develop a comprehensive access strategy for the ring. Johnson & Johnson will lend its expertise and resources as IPM identifies and prioritizes key access activities, from understanding user needs to pricing and commercialization.

In addition to the partnerships that helped develop the ring, IPM is building partnerships across countries and sectors to prepare for the ring’s potential rollout, including:

  • Conducting network mapping and outreach to ensure key stakeholder involvement in all aspects of product delivery;
  • Conducting market research, economic and public health modelling, and demonstration projects and implementation research to inform policymaking;
  • Implementing a robust manufacturing strategy to ensure consistently high-quality products;
  • Developing a supply chain and quality management strategy;
  • Developing informational, educational and communications materials to increase awareness and build demand among women and their partners, communities and health providers; and
  • Identifying financing mechanisms to ensure the ring is provided to women for free or at low cost. 

IPM also established an Access Advisory Committee to provide strategic guidance to help ensure the ring’s successful introduction and uptake in sub-Saharan Africa, where women face the greatest risk for HIV.

Learn about IPM’s early microbicide access collaborations with the WHO and global stakeholders.